Antioxidant activity of vasoactive intestinal peptide in HK2 human renal cells

Peptides

Volumn 38, Issue 2, 2012, Pages 275-281

  Vacas, Eva ^a   Bajo, Ana M ^a   Schally, Andrew V ^b,c   Sánchez Chapado, Manuel ^a,d   Prieto, Juan C ^a   Carmena, María J ^a  

^a UNIVERSITY OF ALCALÁ   (Spain)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^d HOSPITAL UNIVERSITARIO PRÍNCIPE DE ASTURIAS   (Spain)

Author keywords

FPRL 1; H2O2; Oxidative stress; Renal cells; VIP

Indexed keywords

ANTIOXIDANT; DICHLOROFLUORESCEIN; FORMYLPEPTIDE RECEPTOR; FORMYLPEPTIDE RECEPTOR LIKE 1; HYDROGEN PEROXIDE; MONOCLONAL ANTIBODY; PROPIDIUM IODIDE; PROTEIN BAX; PROTEIN BCL 2; REACTIVE OXYGEN METABOLITE; VASOACTIVE INTESTINAL POLYPEPTIDE;

ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; HUMAN; HUMAN CELL; KIDNEY PROXIMAL TUBULE; KIDNEY TUBULE CELL; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN ISOLATION; RENAL PROTECTION; WESTERN BLOTTING;

ANTIOXIDANTS; APOPTOSIS; CELL SURVIVAL; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; HYDROGEN PEROXIDE; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; STRUCTURE-ACTIVITY RELATIONSHIP; TIME FACTORS; VASOACTIVE INTESTINAL PEPTIDE;

EID: 84868683234     PISSN: 01969781     EISSN: 18735169     Source Type: Journal    
DOI: 10.1016/j.peptides.2012.09.011     Document Type: Article

References (49)

1. M.Z. Akin, N. Tunçel, F. Gürer, N. Kural, and S. Uslu Effect of vasoactive intestinal peptide and naloxone combination on urinary N-acetyl-beta-d-glucosaminidase level and kidney histology of rats exposed to severe hemorrhage Pharmacology 47 1993 194 199
2. A. Arimura, M. Li, and B. Batuman Potential protective action of pituitary adenylate cyclase-activating polypeptide (PACAP38) on in vitro and in vivo models of myeloma kidney injury Blood 107 2006 661 668
3. K. Bedard, and K.H. Krause The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology Physiol Rev 87 2007 245 313
4. H. Berisha, H. Foda, H. Sakakibara, M. Trotz, H. Pakbaz, and S.I. Said Vasoactive intestinal peptide prevents lung injury due to xanthine/xanthine oxidase Am J Physiol 259 1990 L151 L155
5. A. Castorina, A. Tiralongo, S. Giunta, M.L. Carnazza, G. Rasi, and V. D'Agata PACAP and VIP prevent apoptosis in schwannoma cells Brain Res 1241 2008 29 35
6. M. Chvanov, O. Petersen, and A. Tepikin Free radicals and the pancreatic acinar cells: role in physiology and pathology Philos Trans R Soc Lond B Biol Sci 360 2005 2273 2284
7. B. Collado, M.J. Carmena, C. Clemente, J.C. Prieto, and A.M. Bajo Vasoactive intestinal peptide enhances growth and angiogenesis of human experimental prostate cancer in a xenograft model Peptides 28 2007 1896 1901
8. B. Collado, M.J. Carmena, M. Sánchez-Chapado, A. Ruíz-Villaespesa, A.M. Bajo, and A.B. Fernández-Martínez Expression of vasoactive intestinal peptide and functional VIP receptors in human prostate cancer: antagonistic action of a growth-hormone-releasing hormone analog Int J Oncol 26 2005 1629 1635
9. B. Collado, I. Gutiérrez-Cañas, N. Rodríguez-Henche, J.C. Prieto, and M.J. Carmena Vasoactive intestinal peptide increases vascular endothelial growth factor expression and neuroendocrine differentiation in human prostate cancer LNCaP cells Regul Pept 119 2004 69 75
10. A. Couvineau, and M. Laburthe VPAC receptors: structure, molecular pharmacology and interaction with accessory proteins Br J Pharmacol 166 2012 42 50
11. A. Dabrowski, S.J. Konturek, J.W. Konturek, and A. Gabryelewicz Role of oxidative stress in the pathogenesis of caerulein-induced acute pancreatitis Eur J Pharmacol 377 1999 1 11
12. M. Delgado, N. Varela, and E. González-Rey Vasoactive intestinal peptide protects against beta-amyloid-induced neurodegeneration by inhibiting microglia activation at multiple levels Glia 56 2008 1091 1103
13. N. El Zein, B. Badran, and E. Sariban VIP differentially activates beta2 integrins, CR1, and matrix metalloproteinase-9 in human monocytes through cAMP/PKA, EPAC, and PI-3K signaling pathways via VIP receptor type 1 and FPRL1 J Leukoc Biol 83 2008 972 981
14. A.B. Fernández-Martínez, A.M. Bajo, M.I. Arenas, M. Sánchez-Chapado, J.C. Prieto, and M.J. Carmena Vasoactive intestinal peptide (VIP) induces malignant transformation of the human prostate epithelial cell line RWPE-1 Cancer Lett 299 2010 11 21
15. A.B. Fernández-Martínez, A.M. Bajo, M. Sánchez- Chapado, J.C. Prieto, and M.J. Carmena Vasoactive intestinal peptide behaves as a pro-metastatic factor in human prostate cancer cells Prostate 69 2009 774 786
16. A.B. Fernández-Martínez, B. Collado, A.M. Bajo, M. Sánchez-Chapado, J.C. Prieto, and M.J. Carmena Vasoactive intestinal peptide induces cyclooxygenase-2 expression through nuclear factor-kappaB in human prostate cell lines. Differential time-dependent responses in cancer progression Mol Cell Endocrinol 270 2007 8 16
17. J.M. Forbes, M.T. Coughlan, and M.E. Cooper Oxidative stress as a major culprit in kidney disease in diabetes Diabetes 57 2008 1446 1454
18. N. Foster, S.D. Hulme, and P.A. Barrow Vasoactive intestinal peptide (VIP) prevents killing of virulent and phoP mutant Salmonella typhimurium by inhibiting IFN-gamma stimulated NADPH oxidative pathways in murine macrophages Cytokine 36 2006 134 140
19. N. Fujimori, T. Oono, H. Igarashi, T. Ito, T. Nakamura, and M. Uchida Vasoactive intestinal peptide reduces oxidative stress in pancreatic acinar cells through the inhibition of NADPH oxidase Peptides 32 2011 2067 2076
20. G. Horvath, R. Brubel, K. Kovacs, D. Reglodi, B. Opper, and A. Ferencz Effects of PACAP on oxidative stress-induced cell death in rat kidney and human hepatocyte cells J Mol Neurosci 43 2011 67 75
21. G. Horvath, B. Racz, P. Szakaly, P. Kiss, E. Laszlo, and L. Hau Mice deficient in neuropeptide PACAP demonstrate increased sensitivity to in vitro kidney hypoxia Transplant Proc 42 2010 2293 2295
22. R. Kalfin, N. Maulik, R.M. Engelman, G.A. Cordis, K. Milenov, and L. Kasakov Protective role of intracoronary vasoactive intestinal peptide in ischemic and reperfused myocardium J Pharmacol Exp Ther 268 1994 952 958
23. M. Kurosawa, and T. Ishizuka Inhibitory effects of vasoactive intestinal peptide on superoxide anion formation by N-formyl-methionyl-leucyl- phenylalanine-activated inflammatory cells in vitro Int Arch Allergy Immunol 100 1993 28 34
24. M. Laburthe, A. Couvineau, and V. Tan Class II G protein-coupled receptors for VIP and PACAP: structure, models of activation and pharmacology Peptides 28 2007 1631 1639
25. P.S. Leung, and Y.C. Chan Role of oxidative stress in pancreatic inflammation Antioxid Redox Signal 11 2009 135 165
26. M. Li, J.L. Maderdrut, J.J. Lertora, A. Arimura, and V. Batuman Renoprotection by pituitary adenylate cyclase-activating polypeptide in multiple myeloma and other kidney diseases Regul Pept 145 2008 24 32
27. B.R. Misra, and H.P. Misra Vasoactive intestinal peptide, a singlet oxygen quencher J Biol Chem 265 26 1990 Sep 15 15371 15374
28. H. Pakbaz, H. Berisha, H. Sharaf, H.D. Foda, and S.I. Said VIP enhances and nitric oxide synthase inhibitor reduces survival of rat lungs perfused ex vivo Ann N Y Acad Sci 723 1994 426 428
29. C.J. Percy, B.K. Pat, H. Healy, D. Johnson, and G. Gobe Phosphorylation of caveolin-1 is anti-apoptotic and promotes cell attachment during oxidative stress of kidney cells Pathology 40 2008 694 701
30. Z. Rekasi, J.L. Varga, A.V. Schally, G. Halmos, P. Armatis, and K. Groot Antagonists of growth hormone-releasing hormone and vasoactive intestinal peptide inhibit tumor proliferation by different mechanisms: evidence from in vitro studies on human prostatic and pancreatic cancers Endocrinology 141 2000 2120 2128
31. S.I. Said The Viktor Mutt memorial lecture. Protection by VIP and related peptides against cell death and tissue injury Ann N Y Acad Sci 921 2000 264 274
32. S.I. Said, H.I. Berisha, and H. Pakbaz N-methyl-d-aspartate receptors outside the central nervous system: activation causes acute lung injury that is mediated by nitric oxide synthesis and prevented by vasoactive intestinal peptide Neuroscience 65 1995 943 946
33. S.I. Said, and V. Mutt Polypeptide with broad biological activity: isolation from small intestine Science 169 1970 1217 1218
34. D.M. Small, J.S. Coombes, N. Bennet, D.W. Johnson, and G.C. Gobe Oxidative stress, anti-oxidant therapies and chronic kidney disease Nephrology 17 2012 311 321
35. S. Sotomayor, M.J. Carmena, A.V. Schally, J.L. Varga, M. Sánchez-Chapado, and J.C. Prieto Transactivation of HER2 by vasoactive intestinal peptide in experimental prostate cancer: antagonistic action of an analog of growth-hormone-releasing hormone Int J Oncol 31 2007 1223 1230
36. N. Tunçel, H. Başmak, K. Uzuner, M. Tunçel, G. Altiokka, and V. Zaimoǧlu Protection of rat retina from ischemia-reperfusion injury by vasoactive intestinal peptide (VIP): the effect of VIP on lipid peroxidation and antioxidant enzyme activity of retina and choroid Ann N Y Acad Sci 805 1996 489 498
37. N. Tunçel, S. Erden, K. Uzuner, G. Altiokka, and M. Tunçel Ischemic-reperfused rat skeletal muscle: the effect of vasoactive intestinal peptide (VIP) on contractile force, oxygenation and antioxidant enzyme systems Peptides 18 1997 269 275
38. N. Tunçel, N. Erkasap, V. Sahintürk, D.D. Ak, and M. Tunçel The protective effect of vasoactive intestinal peptide (VIP) on stress-induced gastric ulceration in rats Ann N Y Acad Sci 865 1998 309 322
39. N. Tunçel, O.T. Korkmaz, N. Tekin, E. Şener, F. Akyüz, and M. Inal Antioxidant and anti-apoptotic activity of vasoactive intestinal peptide (VIP) against 6-hydroxy dopamine toxicity in the rat corpus striatum J Mol Neurosci 46 2012 51 57
40. K. Uzuner, N. Tunçel, Y. Aydin, M. Tunçel, F. Gürer, and P. Benli The effect of vasoactive intestinal peptide (VIP) on superoxide dismutase and catalase activities in renal tissues of rats exposed to hemorrhagic ischemia-reperfusion Peptides 16 1995 911 915
41. E. Vacas, A.B. Fernández-Martínez, A.M. Bajo, M. Sánchez-Chapado, A.V. Schally, and J.C. Prieto Vasoactive intestinal peptide (VIP) inhibits human renal cell carcinoma proliferation Biochim Biophys Acta 1823 2012 1676 1685
42. A. Valdehita, A.M. Bajo, A.B. Fernández-Martínez, M.I. Arenas, E. Vacas, and P. Valenzuela Nuclear localization of vasoactive intestinal peptide (VIP) receptors in human breast cancer Peptides 31 2010 2035 2045
43. A. Valdehita, A.M. Bajo, A.V. Schally, J.L. Varga, M.J. Carmena, and J.C. Prieto Vasoactive intestinal peptide (VIP) induces transactivation of EGFR and HER2 in human breast cancer cells Mol Cell Endocrinol 302 2009 41 48
44. A. Valdehita, M.J. Carmena, A.M. Bajo, and J.C. Prieto RNA interference-directed silencing of VPAC1 receptor inhibits VIP effects on both EGFR and HER2 transactivation and VEGF secretion in human breast cancer cells Mol Cell Endocrinol 348 2012 241 246
45. J.L. Varga, A.V. Schally, V.J. Csernus, M. Zarándi, G. Halmos, and K. Groot Synthesis and biological evaluation of antagonists of growth hormone-releasing hormone with high and protracted in vivo activities Proc Natl Acad Sci U S A 96 1999 692 697
46. J. Yang, T.B. Song, Z.H. Zhao, S.D. Qiu, X.D. Hu, and L. Chang Vasoactive intestinal peptide protects against ischemic brain damage induced by focal cerebral ischemia in rats Brain Res 1398 2011 94 101
47. T. Yoshida, H. Sugiura, M. Mitobe, K. Tsuchiya, S. Shirota, and S. Nishimura ATF3 protects against renal ischemia-reperfusion injury J Am Soc Nephrol 19 2008 217 224
48. R. Yu, H. Zhang, L. Huang, X. Liu, and J. Chen Anti-hyperglycemic, antioxidant and anti-inflammatory effects of VIP and a VPAC1 agonist on streptozotocin-induced diabetic mice Peptides 32 2011 216 222
49. Q. Yuan, S. Hong, S. Han, L. Zeng, F. Liu, and G. Ding Preconditioning with physiological levels of ethanol protect kidney against ischemia/reperfusion injury by modulating oxidative stress PLoS One 6 2011 25811